• Home
  •  James Burton
  • Home
  •  James Burton

James Burton

Professor of Renal Medicine

University of Leicester, UK

Biography

Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.

In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.

He is the current Chair of the UK Kidney Association Clinical Guidelines Committee and has himself chaired a number of UK guideline updates making sure that research translates into clinical practice.

Featured Courses

An Expert Approach to Cardio-Renal Protection in CKD
An Expert Approach to Cardio-Renal Protection in CKD

James Burton Navdeep Tangri David Wheeler et al

  • 2.00 EBAC

Published:

Learning objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

James Burton Shelley Zieroth Clara Bonanad Lozano et al

  • Not accredited

Published:

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more